Current Report Filing (8-k)
January 09 2017 - 6:31AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported):
January
9, 2017
Foundation
Medicine, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-36086
|
|
27-1316416
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
150 Second Street
Cambridge, MA
|
|
02141
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code
(617)
418-2200
Not Applicable
(Former name or former address, if changed
since last report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On January 9, 2017, Foundation Medicine, Inc. (the “Company”) issued a
press release announcing its preliminary financial results for the
quarter and year ended December 31, 2016. A copy of the press release is
being furnished as Exhibit 99.1 to this Report on Form 8-K.
Item 7.01. Other Events.
Michael Pellini, the Company’s Chief Executive Officer, will present at
the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January
10, 2017 at 9:00 a.m. PST in San Francisco. The presentation will be
webcast live through the Company’s website at
investors.foundationmedicine.com. A copy of the presentation slide deck
is being furnished as Exhibit 99.2 to this Report on Form 8-K.
Reference is made to, and there is hereby incorporated by reference into
this Item 7.01, the information set forth above under “Item 2.02.
Results of Operations and Financial Condition.” relating to the press
release announcing preliminary financial results.
The information in this Report on Form 8-K and Exhibits 99.1 and 99.2
attached hereto is intended to be furnished and shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”) or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933, as amended, or
the Exchange Act, except as expressly set forth by specific reference in
such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
|
Description
|
99.1
|
Press release issued by Foundation Medicine, Inc. dated January 9,
2017, furnished hereto.
|
99.2
|
Presentation Slide Deck, furnished hereto.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: January 9, 2017
|
FOUNDATION MEDICINE, INC.
|
|
|
|
|
By:
|
/s/ Robert W. Hesslein
|
|
|
Robert W. Hesslein
|
|
|
Senior Vice President and General Counsel
|
EXHIBIT INDEX
Exhibit No.
|
Description
|
99.1
|
Press release issued by Foundation Medicine, Inc. dated January 9,
2017, furnished hereto.
|
99.2
|
Presentation Slide Deck, furnished hereto.
|
Foundation Medicine, Inc. (NASDAQ:FMI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Foundation Medicine, Inc. (NASDAQ:FMI)
Historical Stock Chart
From Sep 2023 to Sep 2024